Baxter inks R&D deal with Mayo Clinic, initial focus on kidney disease

Baxter (NYSE:BAX) said today that it inked a research & development collaborative deal with the Mayo Clinic to develop new technologies and therapies designed to improve patient therapeutic care.

The pair will initially focus on kidney disease, with additional projects planned in other areas where breakthrough treatment options can be introduced and innovation can improve access to high-quality care.

“We are excited about combining Mayo’s clinical and research expertise with Baxter’s ability to apply and scale innovation. We are confident that this collaboration will help accelerate discoveries, development and application of life-changing therapies for patients,” Florida Mayo Clinic CEO Dr. Gianrico Farrugia said in a prepared statement.

The initial agreement will span 5-years, with a 5-year renewal option. Additional details of the deal were not disclosed.

“Baxter is pleased to work with Mayo Clinic, a world-renowned healthcare organization that shares Baxter’s passion for advancing patient-focused innovation. The combined power of our two organizations will help us advance new solutions to the most pressing healthcare challenges, further delivering on Baxter’s mission to save and sustain lives,” Baxter CEO & chair José Almeida said in a press release.

Earlier this month, Baxter said that after communicating with the FDA, it will pursue a regulatory pathway as a combination product for its new home peritoneal dialysis solution system.

The system is designed to produce sterile PD solutions using a small water filtration device designed to be placed in a patient’s home and integrated into its AMIA automated peritoneal dialysis system, the Deerfield, Ill.-based company said.

The post Baxter inks R&D deal with Mayo Clinic, initial focus on kidney disease appeared first on MassDevice.

from MassDevice http://ift.tt/2rbRhQh